514196-22-6

Upstream product

• 4442-79-9 cyclohexylethan-1-ol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 2295-31-0 thiazoline-2,4-dione 
• 164520-90-5 4-(2-cyclohexylethoxy)benzaldehyde 

Downstream Products

• 1221413-85-9 5-(4-(2-cyclohexylethoxy)benzylidene)-3-(2-hydroxyethyl)-thiazolidine-2,4-dione 
• 1221413-84-8 5-(4-(2-cyclohexylethoxy)benzylidene)-3-methylthiazolidine-2,4-dione 
• 74773-23-2 5-(4-(2-cyclohexylethoxy)benzyl)thiazolidine-2,4-dione 

Relevant academic research and scientific papers

NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF

The present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and the uses thereof. More specifically, the present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and a pharmaceutical composition comprising the same. The novel thiazolidinedione derivatives of formula (I) according to the present invention can be effectively used for the prevention or treatment of cardiovascular disease, gastrointestinal disease and renal disease by inhibiting the activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) that decomposes prostaglandins as well as useful for the prevention of hair loss and the stimulation of hair growth, and osteogenic stimulation and wound healing.

Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors

Novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors were synthesized. Compounds 2, 3, and 4 exhibited IC 50 of 25, 8, and 19 nM, respectively. They also significantly increased levels of PGE2 in A549 cells. To assess the influence of 15-PGDH inhibitor on cochlear blood flow (CBF), 2 was applied intravenously to guinea pigs. It increased their CBFs. Scratch wounds were also analyzed in confluent monolayers of HaCaT cells. Cells exposed to 4 showed significantly improved wound healing with respect to a control.